Losartan Potassium

( DrugBank: Losartan, Potassium / KEGG DRUG: Losartan, Potassium )


5 diseases
IDDisease name (Link within this page)Number of trials
36Epidermolysis bullosa2
98Eosinophilic gastrointestinal disease2
167Marfan syndrome4
IDDisease name (Link within this page)Number of trials
179Williams syndrome1
215Tetralogy of Fallot1

36. Epidermolysis bullosa


Clinical trials : 163Drugs : 185 - (DrugBank : 46) / Drug target genes : 50 - Drug target pathways : 125 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

98. Eosinophilic gastrointestinal disease


Clinical trials : 172Drugs : 149 - (DrugBank : 39) / Drug target genes : 38 - Drug target pathways : 135 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

167. Marfan syndrome


Clinical trials : 21Drugs : 40 - (DrugBank : 11) / Drug target genes : 10 - Drug target pathways : 50 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

179. Williams syndrome


Clinical trials : 5Drugs : 14 - (DrugBank : 7) / Drug target genes : 8 - Drug target pathways : 32 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

215. Tetralogy of Fallot


Clinical trials : 18Drugs : 26 - (DrugBank : 14) / Drug target genes : 13 - Drug target pathways : 45 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries